Drug × Cancer matrix

Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Clear
Showing 29 of 29 matching drugs for HDAC5 — including drugs targeting any of its 16 synthetic-lethal partners , sorted by total cancer coverage.
Drug Target Relationship GBM LUAD SCLC LUSC OAC OSCC PDAC Reposition #cancers
belinostat HDAC5 Direct yes 0
panobinostat HDAC5 Direct yes 0
panobinostat lactate HDAC5 Direct yes 0
romideps HDAC5 Direct yes 0
7-hydroxystaurosporine, irinotecan hydrochloride, diagnostic laboratory biomarker analysis PDPK1 SSL via PDPK1 3
bryostatin 1, paclitaxel PRKCE SSL via PRKCE 2
carboplatin, celecoxib, paclitaxel, adjuvant therapy, conventional surgery, neoadjuvant therapy PDPK1 SSL via PDPK1 2
cpt- 11, cisplatin, celecoxib, radiation, surgery PDPK1 SSL via PDPK1 2
pharmacological study, romidepsin HDAC4 SSL via HDAC4 2
7-hydroxystaurosporine, fluorouracil PDPK1 SSL via PDPK1 1
7-hydroxystaurosporine, gemcitabine hydrochloride, pharmacological study, laboratory biomarker analysis PDPK1 SSL via PDPK1 1
botensilimab, balstilimab, chloroquine phosphate, celecoxib PDPK1 SSL via PDPK1 1
celecoxib, cyclophosphamide, etoposide, thalidomide PDPK1 SSL via PDPK1 1
celecoxib, isotretinoin, temozolomide, thalidomide PDPK1 SSL via PDPK1 1
celecoxib, temozolomide, thalidomide, adjuvant therapy PDPK1 SSL via PDPK1 1
enzastaurin, bevacizumab, enzyme-inducing antiepileptic drugs (eiaed), non-enzyme inducing antiepileptic drugs (neiaed) PIK3R1 SSL via PIK3R1 1
enzastaurin, lomustine PIK3R1 SSL via PIK3R1 1
enzastaurin, temozolomide, radiation therapy PIK3R1 SSL via PIK3R1 1
paclitaxel, bryostatin 1 PRKCE SSL via PRKCE 1
romidepsin HDAC4 SSL via HDAC4 1
romidepsin, azacitidine, nab-paclitaxel, gemcitabine, durvalumab, lenalidomide capsule HDAC4 SSL via HDAC4 1
romidepsin, laboratory biomarker analysis HDAC4 SSL via HDAC4 1
temozolomide, aprepitant, minocycline, disulfiram, celecoxib, sertraline, captopril, itraconazole, ritonavir, auranofin PDPK1 SSL via PDPK1 1
topotecan hydrochloride, 7-hydroxystaurosporine PDPK1 SSL via PDPK1 1
belinostat HDAC4 SSL via HDAC4 yes 0
midostaurin PRKCE SSL via PRKCE yes 0
panobinostat HDAC4 SSL via HDAC4 yes 0
panobinostat lactate HDAC4 SSL via HDAC4 yes 0
romideps HDAC4 SSL via HDAC4 yes 0
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable list from cansar.ai.